Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  mercaptopurine tablet
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-16 of 16 for your search:
Start Over
Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under at diagnosis
Sponsor: Other
Protocol IDs: 6-MP formulation, 2013-001236-21, NCT01906671
Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: IICIA -PTX02, NCT02451774
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: NOPHO ALL2008 consolidation, NCT00816049
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to < 10
Sponsor: NCI, Other
Protocol IDs: AALL0932, NCI-2011-02599, CDR0000683227, U10CA098543, COG-AALL0932, NCT01190930
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI, Other
Protocol IDs: AALL1131, NCI-2011-03797, CDR0000706370, U10CA098543, COG-AALL1131, NCT01406756
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis, Educational/Counseling/Training
Status: Active
Age: 12 to 20
Sponsor: NCI, Other
Protocol IDs: ACCL1033, NCI-2012-00105, CDR0000721559, COG-ACCL1033, U10CA095861, NCT01503632
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 35 to 70
Sponsor: NCI
Protocol IDs: NCI-2013-02229, ECOG-E1910, E1910, U10CA180820, U10CA021115, NCT02003222
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 30
Sponsor: NCI
Protocol IDs: NCI-2014-00712, AALL1231, U10CA180886, U10CA098543, NCT02112916
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: ALLR18, NCT01700946
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01047, SWOG-S1318, S1318, U10CA180888, NCT02143414
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LBL-308, NCT02396043
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 12 to 30
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 2014-0396, NCT02419469
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: RELMLL, NCI-2015-00602, NCT02419755
Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 10 and over
Sponsor: Other
Protocol IDs: 2014-0521, NCT02420717
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Phase: Phase I
Type: Treatment
Status: Active
Age: 51 to 75
Sponsor: Other
Protocol IDs: 14-200, NCT02228772
Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 to 17
Sponsor: Other
Protocol IDs: 6-MP pharmacokinetic 1, NCT01324336
Start Over